Ge discovery 690

¹⁸F-DCPyL for both centres was sourced from Cyclotek (Melbourne, Australia and Wellington, New Zealand) produced by the same method described previously [14 ].
PRC: Patients were required to drink 1–2L of water prior to their appointment and void immediately prior to scanning. No diuretics were administered. Patients were imaged on a GE Discovery 690 (General Electric Medical Systems, Milwaukee WI, USA). Low-dose attenuation correction CT images were acquired and reconstructed to 3.75 mm slice thickness with an increment of 3.27 mm using iterative reconstruction (50% ASiR). All patients at both centres were administered 250 MBq (± 50 MBq) of 18F-DCFPyL intravenously in accordance with reference standards outlined by the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) [15 ]. Imaging was performed at 120 min (± 10 min) after injection. PET images were acquired at 3.5 min/bed through the pelvis and 3.0 min/bed to the lung apices. Images were reconstructed from time of flight emission data using VUE Point FX and Q-Clear™ “GE Healthcare” iterative technique with a β value of 400. Sharp IR function was applied with no Z-axis filter. PET images were reconstructed on a 256 matrix.
STV: Patients were imaged on a GE Discovery 710 PET/CT (General Electric Medical Systems, Milwaukee WI, USA). Otherwise the scanning protocol matched that described above.

All patients underwent [⁶⁸Ga]Ga-DOTATATE PET-CT of the whole body 55–70 min after intravenous bolus injection of 200 ± 11 MBq (5.4 ± 0.3 mCi) of [⁶⁸Ga]Ga-DOTATATE. PET-CT images were acquired on a GE Discovery-690 16 slice integrated PET-CT scanner (GE Healthcare) without IV contrast. CT scan of the skull base to proximal thighs (80–120 mA) was utilized for anatomic imaging and correction of emission data. PET images were acquired in 3-min scan time per bed position PET acquisition. Dead time, detector efficiency and scatter corrections were applied using the routines supplied by the manufacturer. The resulting images were quantitatively calibrated with 6 mm isotropic resolution. Images were reconstructed with the iterative technique and reviewed on a MimVista workstation (MIM Software, Version 7.2.1). Reconstruction parameters were VUE point FX with 3 iterations/24 subsets and 6.4 mm filter cutoff, and the reconstructed slice thickness was 3.75 mm.

Single bed position image acquisition centred on the tumour was performed with GE Discovery 690 or 710 PET-CT Scanners (GE Healthcare) for 10 min at 2 and 4 h following the administration of 18F-Fluoromisonidazole (FMISO) (manufactured by University of Cambridge) with an activity of 370 MBq. Precursor (1-(2′-Nitro-1′-imidazolyl)-2-O-tetrahydropyranyl-3-O-toluenesulfonyl-propanediol, NITTP) was used from Advanced Biochemical Compounds (ABX) and the synthesis of FMISO was performed on a FASTlab synthesis module (GE Healthcare) according to the manufacturer’s instructions. The product was then sterilized by filtration through a Millex-GV 0.22 µm sterile filter (Merck Millipore)^{35 (link)}.
The same scanner was used for the two visits of each patient with baseline scans and pre-surgery scans for atovaquone-treated and untreated patients. CT images provided attenuation correction and localization. All PET images were reconstructed with a Bayesian penalised-likelihood algorithm, Q.Clear (GE Healthcare) using a beta value of 400^{36 (link)}. As with previous work, respiratory motion correction was not performed for the presented analysis^{38 (link)}. Patients in cohort 1 had a median length of 13.5 (IQR 10.75–14) days between imaging timepoints, depending on their planned date for surgery. Patients in cohort 2 had a median length of 14 (IQR 7–14) days between imaging timepoints.

To explore the detection limit of ⁸⁹Zr-labeled cells on a human PET scanner, ⁸⁹Zr-labeled Jurkat cells were seeded in RPMI medium into 6-well plates at different specific activities, ranging from 10⁴ to 10⁶ cells per well. Additionally, varying concentrations of ⁸⁹Zr-labeled cells suspended in Geltrex™ matrix were placed into a 3 × 3-well plate containing 1 cm³ cubic wells in order to examine the effect of cell density on detection. The 6-well plates and 3 × 3 cubic-well plate were imaged on clinical PET/CT (GE Discovery 690) and PET/MR (GE SIGNA) systems (GE Healthcare, Waukesha, USA). The total radioactivity (kBq) in each of the cell suspensions was determined by well counter measurements. The specific activity (SA), defined here as the radioactivity per 10⁶ cells (kBq/10⁶ cells), was calculated for each well based on the corresponding well counter measurement divided by the total number of cells as counted in a hemocytometer. For the 1-cm³ cubic wells, cell density (10⁶ cells/mL) was defined as the number of cells contained in the 1-mL well volume. A detailed account of the experimental procedure is provided in the Supporting Information Section 4.

Integrated PET-CT was performed before EBUS-TBNA in all patients at 3 accredited Australian PET centers according to standard institutional protocols using one of GE discovery 690 (GE Medical Systems, Milwaukee, WI), Discovery STE (GE Medical Systems), or Biograph 64/40 (Siemens Medical Solutions, Malvern, PA).

All patients underwent a respiratory-gated (4D) PET-CT lung perfusion scan using a procedure that we have previously described [15 (link)]. Patients were imaged on a GE Discovery 690 PET/CT scanner (GE Medical Systems Milwaukee, WI, USA) after injection of approximately 50 MBq of ⁶⁸Ga-MAA [7 (link)]. The perfusion PET was acquired as a two-bed acquisition encompassing the apex to base of both lungs planned by a scout CT. Each bed position was acquired for 5 min.

All FDG-PET scans were acquired in the morning at approximately 11 am. Patients were asked to stop anti-Parkinson medication on the day of the PET scan. Blood glucose levels were measured prior to the injection of fluorodeoxyglucose and verified to be <160 mg/ml in all study patients. 3D brain PET acquisition was performed using a GE Discovery 690 PET-CT scanner 30 min after the IV administration of 5-7 mCi (185-259 MBq) fluorodeoxyglucose over a period of 15 min. Subjects remained with eyes open at rest in a dimly lit room during the tracer uptake period. Images were attenuation corrected using a CT scan of 120 kV and automated mA, and reconstructed using a 2.5 mm slice thickness and the standard PET-CT reconstruction algorithms on the GE 690 Discovery system.